Julie M. Reed, the new executive director of the Biosimilars Forum, gives a timeline of her career in the biosimilars space and what led her to be one of the founders of the organization.
Julie M. Reed, the new executive director of the Biosimilars Forum, gives a timeline of her career in the biosimilars space and what led her to be one of the founders of the organization.
Transcript
You are one of the founders of the Biosimilars Forum. What was it about biosimilars that got you involved with this line of work in the first place?
So, I'm old and I've had an incredible career, where my first job was as a clinician and then as a hospital administrator and nursing home administrator. Then I moved over into pharma. And I've always been mainly on the generic drug side. And then, as I developed my career in government affairs and policy, I was with Hospira. Hospira was one of the first biosimilar companies in the world. My CEO and the board decided that biosimilars and creating a biosimilars pathway was a major strategic goal. And so with my health care background, my generic drug background, and my working with patients and seeing the cost of health care, it was quite an honor to be to be tapped on the shoulder and say, "Julie, our strategic priority is to develop a biosimilars pathway and we we want you to go do that."
So, I been there from the beginning, not just in biosimilars in the United Staes and lobbying to get the BPCIA [Biologics Price Competition and Innovation Act] passed, I've also worked around the world helping to develop the pathways and launched biosimilars in Europe and Japan and everywhere where nobody knew what a biosimilar was; it was a new word. Can you imagine? And we had to tell everybody what it meant and what it was about and how policies had to change.
I was, I hope, a driving force and continue to be a driving force in seeing that happen. So, it's a passion of mine, and it's been an incredibl amount of fun.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.